Thus, we conclude that wedelolactone partially suppresses the production of MSU‐elevated IL‐1β and caspase‐1 (p20) in vivo, thereby limiting NLRP3 inflammasome activation and neutrophil influx, suggesting that wedelolactone may be a potential candidate in the treatment of gouty arthritis. Here, NLRP3 is linked to gout.